Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NRAS wild-type

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

NRAS mutation (125)

RAS wild-type (17)

NRAS mutation + BRAF mutation (4)

FLT3 mutation + NRAS mutation (3)

NRAS Q61K + BRAF V600E (3)

NRAS exon 2 mutation (3)

NRAS exon 4 mutation (3)

EGFR mutation + NRAS Q61K (2)

NRAS G12C + BRAF mutation (2)

NRAS exon 3 mutation (2)

ARAF mutation + NRAS mutation (1)

ASXL1 mutation + NRAS mutation (1)

BRAF wild-type + NRAS wild-type (1)

DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

DNMT3A mutation + NRAS mutation (1)

EGFR exon 20 insertion + NRAS G13V + NF1 R69fs + NF1 S340fs (1)

FLT3 mutation + NRAS mutation + PTPN11 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)

FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

HRAS Q61L + NRAS Q61K (1)

IDH2 mutation + NRAS mutation (1)

NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)

NPM1 mutation + NRAS mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

NRAS G115Efs*46 (1)

NRAS G12C + BRAF V600E + BRAF V600D (1)

NRAS G13D + BRAF V600E (1)

NRAS mutation + U2AF1 mutation (1)

SETBP1 mutation + NRAS mutation (1)

SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

TET2 mutation + NRAS mutation (1)

NRAS mutation (125)

RAS wild-type (17)

NRAS mutation + BRAF mutation (4)

FLT3 mutation + NRAS mutation (3)

NRAS Q61K + BRAF V600E (3)

NRAS exon 2 mutation (3)

NRAS exon 4 mutation (3)

EGFR mutation + NRAS Q61K (2)

NRAS G12C + BRAF mutation (2)

NRAS exon 3 mutation (2)

ARAF mutation + NRAS mutation (1)

ASXL1 mutation + NRAS mutation (1)

BRAF wild-type + NRAS wild-type (1)

DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

DNMT3A mutation + NRAS mutation (1)

EGFR exon 20 insertion + NRAS G13V + NF1 R69fs + NF1 S340fs (1)

FLT3 mutation + NRAS mutation + PTPN11 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)

FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

HRAS Q61L + NRAS Q61K (1)

IDH2 mutation + NRAS mutation (1)

NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)

NPM1 mutation + NRAS mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

NRAS G115Efs*46 (1)

NRAS G12C + BRAF V600E + BRAF V600D (1)

NRAS G13D + BRAF V600E (1)

NRAS mutation + U2AF1 mutation (1)

SETBP1 mutation + NRAS mutation (1)

SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

TET2 mutation + NRAS mutation (1)

›

Related tests:

FoundationOne® CDx (110)

MI Cancer Seek™

FoundationOne® CDx (110)

MI Cancer Seek™

NRAS wild-type	Rectal Cancer	NRAS wild-type	Rectal Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
NRAS wild-type	Colon Cancer	NRAS wild-type	Colon Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
NRAS wild-type	Colon Cancer	NRAS wild-type	Colon Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
NRAS wild-type	Rectal Cancer	NRAS wild-type	Rectal Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	panitumumab Sensitive: C2 – Inclusion Criteria panitumumab Sensitive : C2	panitumumab Sensitive: C2 – Inclusion Criteria panitumumab Sensitive : C2
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
NRAS wild-type	Colorectal Cancer	NRAS wild-type	Colorectal Cancer	SCT200 Sensitive: C3 – Early Trials SCT200 Sensitive : C3	SCT200 Sensitive: C3 – Early Trials SCT200 Sensitive : C3
NRAS wild-type	Melanoma	NRAS wild-type	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
NRAS wild-type	Glioblastoma	NRAS wild-type	Glioblastoma	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3